Semaglutide
STEP-HFpEF
Novo Nordisk · Phase 3 · Completed · Enrollment 529
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Semaglutide | n/r | 34.1% | 56.1% | 76.4% |
| Placebo (semaglutide) | n/r | 90.5% | 97.9% | 99.6% |
Not shown
Every selected arm is drawn.